GPAS users can process genomic sequence data in up to four hours to be able to identify and analyse variants of concern. This helps to inform research and policy decisions in real time. All personal identifiable information (PII) is removed before data enters the cloud, users control whether or not to share data, and the data can be loaded into any global sequence repository – including GISAID, EBI and ENA.
GPAS will be a powerful tool for public health agencies across the globe. It will allow them to quickly identify features such as VOCs and antimicrobial resistance as they develop, and will be easily identifiable.
Local healthcare institutes with the ability to sequence SARS-CoV-2 will be able to get rapid data analysis to enable early, on the ground, interventions once VOCs are identified. GPAS will also influence therapeutic and drug treatment options on a same-day basis.
GPAS is already a collaboration of multiple universities and academic institutes. Its scope will grow with new partners and allow easy data sharing between countries and establishments. It will also enable identification of similar strains and hopefully lead to ongoing collaborative research in epidemiology, therapeutics and diagnostics of multiple pathogens starting with SARS-CoV02 and TB.
Institute of Public Health of Chile
Oxford Nanopore Technologies
Oxford University Clinical Research Unit
Muhimbili University of Health and Allied Sciences
Centre de Recherche du Centre Hospitalier de l’Université de Montréal (CRCHUM)
Institute of Clinical Pathology and Medical Research – New South Wales Pathology, Westmead Hospital
National Institute for Communicable Diseases
Wits Health Consortium (University of the Witwatersrand)
GPAS is part of the UK Health Security Agency’s New Variant Assessment Platform
Our real-time data and insights support policy and scientific responses to the COVID-19 pandemic as well as other outbreaks and endemic diseases. Our vision covers three simple steps:
Inputting relevant data.
Disseminating source, identity and trends.
Informed research, trials and public health response.
Contact us for demos and more detailed information on the solution. We are also interested in exploring further opportunities for partnership.